IP Library Granted Patent US 9,872,877
Granted Patent B2
US 9,872,877 · App. 15/203,684 · Granted Jan 23, 2018

Methods of using regenerative cells to promote epithelialization or neodermis formation

Inventors: John K. Fraser (San Diego, CA); Marc H. Hedrick (Solana Beach, CA); Eric Daniels (San Diego, CA)
Assignee: Cytori Therapeutics, Inc.
A61K35/28A61K9/0014A61K35/12A61K35/35A61K35/36A61K35/44A61K38/1866A61K45/06A61L15/40A61L15/44A61L27/3604A61L27/3834A61L27/54A61L27/56C12N5/069C12N5/0667A61L2300/412A61L2300/64C12N2506/1384
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,872,877
App. No.
15/203,684
Granted
Jan 23, 2018
Kind
B2
Abstract

Cells present in adipose tissue are used to promote wound healing in a patient. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the regenerative cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Claims (26)

1. A method of inducing epithelialization or neodermis formation at a wound of the skin of a subject, comprising:

identifying a subject with an wound; and

administering a therapeutically effective amount of a concentrated population of adipose-derived regenerative cells comprising adipose-derived stem cells and endothelial progenitor cells to said subject sufficient to accelerate the healing of said wound, wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells.

2. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells has not been cultured.

3. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells is obtained from adipose tissue of the subject to whom the cells are administered.

4. The method of claim 1 , wherein said administering step comprises applying the concentrated population of adipose-derived regenerative cells directly to the wound.

5. The method of claim 1 , wherein the wound is a diabetic ulcer.

6. The method of claim 1 , wherein the subject has peripheral vascular disease.

7. The method of claim 1 , wherein said administering step comprises subcutaneous delivery.

8. The method of claim 1 , wherein said administering step comprises dermal delivery.

9. The method of claim 1 , wherein the subject is obese.

10. The method of claim 1 , wherein said administration step comprises administering multiple doses of said concentrated population of adipose-derived regenerative cells.

11. The method of claim 1 , further comprising:

providing adipose tissue to a self-contained adipose tissue processing unit comprising:

a tissue collecting container configured to receive and fully or partially disaggregate adipose tissue, wherein said tissue collecting container is coupled to a cell collection container wherein said coupling defines a closed system in which said fully or partially disaggregated adipose tissue directed from tissue collecting container to cell collection container is not exposed to the external environment; and wherein said cell collection container, further comprises a cell concentrator that facilitates separation of the cells in a suspension; and

an outlet that is structured to permit said concentrated population of adipose-derived regenerative cells comprising adipose-derived stem and endothelial progenitor cells to be removed from said adipose tissue processing unit;

obtaining the concentrated population of adipose-derived regenerative cells from said self-contained adipose tissue processing unit.

12. The method of claim 1 , wherein the therapeutically effective amount of the concentrated population of adipose-derived regenerative cells comprises a minimum concentration of between 1×10 5 and 1×10 7 adipose-derived stem cells.

13. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells further comprises an additive.

14. The method of claim 13 , wherein said additive is selected from the group consisting of a cell differentiation factor, a growth promoter, an immunosuppressive agent, a medical device, or a combination thereof.

15. The method of claim 13 , wherein said additive is selected from the group consisting of other cells, tissue, and tissue fragments.

16. The method of claim 13 , wherein said additive comprises an angiogenic factor, or an arteriogenic factor.

17. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells is applied to a biocompatible matrix.

18. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells is applied to a bandage.

19. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells is not exposed to the external environment prior to the administration step.

20. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells is cryopreserved.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 049313 FRAME: 0434. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 1, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049942/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049313/0434 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2019
From: OXFORD FINANCE LLC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 049011/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2019
From: CYTORI THERAPEUTICS, INC.
To: LOREM VASCULAR PTE. LTD.
Reel/Frame 049651/0001 →
SECURITY INTEREST Recorded Sep 22, 2017
From: CYTORI THERAPEUTICS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 043952/0150 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 12203684 PREVIOUSLY RECORDED ON REEL 043285 FRAME 0848. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 17, 2017
From: FRASER, JOHN K.; HEDRICK, MARC H.; DANIELS, ERIC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 043592/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2017
From: FRASER, JOHN K.; HEDRICK, MARC H.; DANIELS, ERIC
To: CYTORI THERAPEUTICS, INC.
Reel/Frame 043285/0848 →
Continuity (6)
Continuation 14180553 · Feb 14, 2014
Division 13360022 · Jan 27, 2012
Division 10884860 · Jul 1, 2004
Continuation In Part 10316127 · Dec 9, 2002
Provisional Application 60338856 · Dec 7, 2001
Related Publication 20160310540A1 · Oct 27, 2016